A practical reference on 稳定性: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
In 2019, upon identification of a causal relation between Allergan Biocell breast prostheses (with a textured surface) and an immune-system cancer [anaplastic, large-cell lymphoma (BIA-ALCL)], the FDA recalled every model of prosthetic breast made by the Allergan Biocell company.
The Mojave rattlesnake is widely regarded as producing one of the most toxic snake venoms in the New World, based on LD50 studies in laboratory mice. Their potent venom is the result of a presynaptic neurotoxin composed of two distinct peptide subunits. The basic subunit (a phospholipase A2) is mildly toxic and apparently rather common in North American rattlesnake venoms. The less common acidic subunit is not toxic by itself, but in combination with the basic subunit, produces the potent neurotoxin called "Mojave toxin". Nearly identical neurotoxins have been discovered in five North American rattlesnake species besides the Mojave rattlesnake. However, not all populations express both subunits. The venom of many Mojave rattlesnakes from south-central Arizona lacks the acidic subunit and has been designated "venom B", while Mojave rattlesnakes tested from all other areas express both subunits and have been designated "venom A" populations.
==== Eliminated in primary ==== William Abel, U.S. Army veteran David Berry, physician Steve Dowell, U.S. Army veteran Edward Ewald, retiree Abhiram Garapati, real estate investor Valentina Gomez, financial strategist and candidate for Missouri Secretary of State in 2024 (previously ran in the 2nd district) Raymond Hamden, real estate broker Elvis Lossa, policy coordinator Vince Offer, pitchman and comedian
== Diagnosis == On clinical examination, crackles are common, and more rarely, patients may have clubbing (<5% of cases). Laboratory findings are nonspecific but inflammatory markers such as the erythrocyte sedimentation rate or C-reactive protein and the lymphocyte count are frequently elevated. If the organizing pneumonia is secondary to a connective tissue disorder, then the associated laboratory values such as the anti-nuclear antibody, rheumatoid factor, anti-citrullinated protein antibodies, anti-dsDNA antibodies and other similar connective tissue associated antibodies are elevated. Pulmonary function testing in people with organizing pneumonia, either cryptogenic or due to secondary causes, shows a restrictive defect with a decrease in the gas absorptive capacity of the lungs (seen as a decrease in the diffusion capacity of carbon monoxide). Airflow obstruction is usually not seen on pulmonary function testing. Bronchoscopy with bronchoalveolar lavage is recommended in possible cases of organizing pneumonia to rule out infection and other causes of alveolar infiltrates. The bronchoalveolar lavage in organizing pneumonia shows a lymphocytic predominant inflammation of the alveoli with increases in neutrophils and eosinophils. Resolution of inflammatory cells in the bronchoalveolar lavage is usually delayed in organizing pneumonia, lagging behind clinical and radiographic improvement. Biopsy findings in patients with organizing pneumonia consist of loose connective tissue plugs involving the alveoli, alveolar ducts and bronchioles.
=== Effective altruism === Effective accelerationism diverges from the principles of effective altruism, which prioritizes using evidence and reasoning to identify the most effective ways to altruistically improve the world. This divergence comes primarily from one of the causes effective altruists focus on – AI existential risk. Effective altruists (particularly longtermists) argue that AI companies should be cautious and strive to develop safe AI systems, as they fear that any misaligned AGI could eventually lead to human extinction. Proponents of effective accelerationism generally consider existential risks from AGI to be negligible, and claim that even if they were not, decentralized free markets would much better mitigate this risk than centralized governmental regulation.
Sources: en.wikipedia.org
The electoral process for the president was also changed, from being directly elected by the Togolese people to being indirectly elected by the Parliament. Opposition members criticised these changes due to the lack of term limits for Gnassingbé's new position. The changes came into effect in May 2025, when Gnassingbé was sworn in as president of the Council of Ministers, with former opposition leader Jean-Lucien Savi de Tové becoming president. Since June 2025, protests against Gnassingbé grew demanding his resignation. Gnassingbé has been widely criticized for contributing to democratic backsliding in Togo and critics have described him as a dictator.
== Lithium carbonate equivalent == Lithium carbonate equivalent, abbreviated LCE, is an industry standard for lithium compounds whose lithium content is expressed in weight-equivalent of lithium carbonate. The term is commonly used in the lithium mining industry.
Also that year, Schumer wrote a memoir, entitled The Girl with the Lower Back Tattoo. It held the top position on The New York Times Non-Fiction Best Seller list for two weeks in September 2016 and garnered her a nomination for the Grammy Award for Best Spoken Word Album. Schumer made her Broadway debut in 2017 acting in Steve Martin's comedy play Meteor Shower alongside Keegan-Michael Key, Laura Benanti and Jeremy Shamos. The play revolves around two couples in 1993 who spend an evening with each other. David Rooney of The Hollywood Reporter wrote "Schumer is one of four terrific performers who juice the entertainment of this high-sheen production...which would never have made it this far without Martin's name behind it, or more crucially, without the marquee draw of Schumer making her Broadway debut." Schumer was nominated for the Tony Award for Best Actress in a Play losing to Glenda Jackson for the revival of Edward Albee's Three Tall Women. In 2018, she starred in the comedy film I Feel Pretty which received negative reviews from critics. Spotify released the original podcast Amy Schumer Presents: 3 Girls, 1 Keith on June 21, 2018, starring Schumer and her best comedy friends Rachel Feinstein, Bridget Everett and Keith Robinson as they talk about comedy, pop culture, politics and their personal lives. She released her standup special Amy Schumer: Growing (2019) on Netflix to positive reviews. Schumer received a Primetime Emmy Award for Outstanding Writing for a Variety Special nomination.
In the early part of 1982, Carrey reportedly performed for The Tonight Show bookers Jim McCawley and Bud Robinson as part of the program's audition process for stand-up comic spots. However, rather than being booked on the show, Carrey got advised to further hone his act, so he went back home to the Toronto area where he had already built a significant following. Touring venues throughout North America as the opening act for Rodney Dangerfield, Carrey made a stop at home in Toronto on June 19, 1982, performing two sold-out shows at Massey Hall.
Albert Grünwedel, one of the German discovers of the Kizil Caves, found in Saint-Peterburg a 13th-century Tibetan text related to Kucha and the Kizil Caves, including a map, which describes the caves from the perspective of Tantric Buddhism. According to the Tibetan text, the paintings in some of the caves were commissioned by a Tokharian (Thogar) king called "Mendre" (probably Māndhātṛ) with the advice of Anandavarman, a high-ranking monk. The king ordered an Indian artist, Naravahanadatta, and a Syrian artist, Priyaratna, with their disciples to paint the caves. The neighbouring Khotanese kings Vijayavardhana and Murlimin also assisted with the painting of another cave by sending artists to the site.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.